Immix Biopharma, Inc.
IMMX
$8.18
$0.172.12%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -40.89% | -14.54% | -45.79% | 5.60% | 32.69% |
| Total Depreciation and Amortization | -32.84% | 69.05% | 34.80% | 43.34% | 59.46% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 21.32% | -11.59% | -38.71% | 23.06% | -3.83% |
| Change in Net Operating Assets | -193.36% | 53.36% | -63.69% | -25.46% | 10.00% |
| Cash from Operations | -86.76% | -11.22% | -215.10% | -14.15% | 63.43% |
| Capital Expenditure | 55.68% | -191.93% | -88.48% | 86.65% | -86.81% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1,684.16% | -191.93% | -88.48% | 86.65% | -86.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 787.61% | 870.62% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 117.87% | -- | -- | -- | -- |
| Cash from Financing | 801.84% | 855.60% | -- | -- | -- |
| Foreign Exchange rate Adjustments | 43.20% | -146.71% | 651.25% | 68.13% | -209.13% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,709.56% | 200.61% | -143.24% | 12.33% | 53.12% |